Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.

Medaglini D; Siegrist CA

doi:10.1016/j.coviro.2017.03.008

Back

Journal article

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.

Medaglini D Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Siegrist CA World Health Organization Collaborating Center for Vaccine Immunology, Departments of Pathology-Immunology, University of Geneva, 1211 Geneva, Switzerland. Electronic address: claire-anne.siegrist@unige.ch.

2017-05-02

Published in:

Current opinion in virology. - 2017

English The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature.

Language